Evidence map›Paper›PMID 37367059›Full record

ArticleCurrent issues in molecular biology2023

Hae Jin Lee, So Jung Lee, Sung Kwon Lee, Bong Keun Choi, Dong Ryung Lee, Ju-Hyoung Park, Joa Sub Oh

Open access · goldAbstract read
In one paragraph

Article in Current issues in molecular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Novel Osteoblastogenic Activity ofInternational journal of molecular sciences · 2026
    Article
  2. Frontiers in pharmacology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hae Jin LeeNUON Co., Ltd., Jungwon-gu, Seongnam-si 13201, Republic of Korea.
So Jung LeeNUON Co., Ltd., Jungwon-gu, Seongnam-si 13201, Republic of Korea.
Sung Kwon LeeNUON Co., Ltd., Jungwon-gu, Seongnam-si 13201, Republic of Korea.
Bong Keun ChoiNUON Co., Ltd., Jungwon-gu, Seongnam-si 13201, Republic of Korea.
Dong Ryung LeeNUON Co., Ltd., Jungwon-gu, Seongnam-si 13201, Republic of Korea.
Ju-Hyoung ParkCollege of Pharmacy, Dankook University, Cheonan 31116, Republic of Korea.
Joa Sub OhCollege of Pharmacy, Dankook University, Cheonan 31116, Republic of Korea.
Dankook University · KR

Funding

Korea Forest Service 2021373B10-2223-BD-02
6 · The paper itself

Abstract

Clinical prevention is of utmost importance for the management of periodontal diseases. Periodontal disease starts with an inflammatory response in the gingival tissue, and results in alveolar bone destruction and subsequent tooth loss. This study aimed to confirm the anti-periodontitis effects of MKE. To confirm this, we studied its mechanism of action using qPCR and WB in LPS-treated HGF-1 cells and RANKL-induced osteoclasts. We found that MKE suppressed proinflammatory cytokine protein expression by inhibiting the TLR4/NF-κB pathway in LPS-PG-induced HGF-1 cells and blocking ECM degradation by regulating the expression of TIMPs and MMPs. We also confirmed that TRAP activity and multinucleated cell formation were reduced in RANKL-stimulated osteoclasts after exposure to MKE. These results were confirmed by inhibiting TRAF6/MAPK expression, which led to the suppression of

Indexed as

bone resorptionECM degradationgingival tissue destructionhuman gingival fibroblastinflammationMagnolia kobusosteoclastperiodontitis

Identifiers

PMID37367059
PMCPMC10297525
OpenAlexW4379384957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.